Drugmakers including BioNTech, Merck & Co. and Pfizer are all testing their investigational PD-1/VEGF bispecifics against lung tumors. But while trial results look favorable, there is reason for ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PARK CITY, Utah — In this Healio Video Perspective from ...
Real-world diabetic macular edema care lags trials as fewer VEGF injections and step therapy limit outcomes. Persistent ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Fexagratinib targets FGF, CSF, and VEGF pathways, showing potential in MS treatment by reducing inflammation and promoting remyelination. Mouse models demonstrated significant prevention and ...
A massive 10-year population study reveals that neovascular age-related macular degeneration (nAMD) is linked to an increased ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Some patients are suboptimal responders to anti-VEGF ...
Dual PD-L1 and VEGF-A blockade with pumitamig plus chemotherapy yielded a 70% overall response rate and 100% disease control in evaluable first-line advanced NSCLC without actionable alterations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results